ArticleCost effectiveness and resource allocation : C/E2024

Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study.

Areej S Albahdal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.